NASDAQ:KDNY

Chinook Therapeutics Stock Forecast, Price & News

$13.89

+0.29 (+2.13 %)

(As of 04/13/2021 01:20 PM ET)

Add

Compare

Today's Range

$13.66

Now: $13.89▼

$14.07

50-Day Range

$14.38

MA: $16.80▼

$19.11

52-Week Range

$10.50

Now: $13.89▼

$21.68

Volume1,921 shs

Average Volume118,286 shs

Market Capitalization$588.62 million

P/E RatioN/A

Dividend YieldN/A

Beta0.26

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, an investigational Phase III ready endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates include BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, a preclinical development candidate for an undisclosed ultra-orphan kidney disease, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook Therapeutics, Inc. is based in Seattle, Washington.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:KDNY

Previous Symbol

CUSIPN/A

CIKN/A

Webchinooktx.com

Phone510-848-4400

Employees43

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio11.27

Quick Ratio11.27

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$17.26 million

Price / Sales34.10

Cash FlowN/A

Price / Cash FlowN/A

Book Value$4.07 per share

Price / Book3.41

Profitability

EPS (Most Recent Fiscal Year)($5.15)

Net Income$-82,370,000.00

Net Margins-215.80%

Return on Equity-112.72%

Return on Assets-21.36%

Miscellaneous

Outstanding Shares42,377,000

Market Cap$588.62 million

Next Earnings Date5/3/2021 (Estimated)

OptionableOptionable

Headlines

Q1 2021 EPS Estimates for Chinook Therapeutics, Inc. Reduced by Wedbush (NASDAQ:KDNY)
April 12, 2021 | americanbankingnews.com

Chinook Therapeutics (NASDAQ:KDNY) Issues Quarterly Earnings Results
April 8, 2021 | americanbankingnews.com

Chinook Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
April 7, 2021 | finance.yahoo.com

Chinook Therapeutics Announces First Patient Dosed in Phase 2 AFFINITY Basket Study of Atrasentan in Proteinuric Glomerular Diseases
April 7, 2021 | finance.yahoo.com

Chinook Therapeutics Announces Update on Non-Renal Legacy Programs from Aduro Biotech Merger
April 5, 2021 | finance.yahoo.com

Chinook Therapeutics, Inc. Forecasted to Post Q1 2022 Earnings of ($0.58) Per Share (NASDAQ:KDNY)
April 2, 2021 | americanbankingnews.com

Chinook (KDNY) Surges 7%: Is This an Indication of Further Gains?
March 31, 2021 | finance.yahoo.com

Chinook Therapeutics (NASDAQ:KDNY) Trading Down 9%
March 31, 2021 | americanbankingnews.com

Chinook Therapeutics Announces Upcoming Data Presentations at ISN World Congress of Nephrology 2021 and 58th ERA-EDTA Congress
March 30, 2021 | finance.yahoo.com

Chinook Therapeutics (NASDAQ:KDNY) Sees Strong Trading Volume
March 30, 2021 | americanbankingnews.com

Chinook Therapeutics (NASDAQ:KDNY) Stock Price Down 4.8%
March 25, 2021 | americanbankingnews.com

Chinook Therapeutics (NASDAQ:KDNY) Receives Buy Rating from Bloom Burton
March 25, 2021 | americanbankingnews.com

Chinook Therapeutics (NASDAQ:KDNY) Sees Large Volume Increase
March 24, 2021 | americanbankingnews.com

Chinook Therapeutics, Inc. (NASDAQ:KDNY) Receives Average Recommendation of "Buy" from Brokerages
March 21, 2021 | americanbankingnews.com

Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 ALIGN Study of Atrasentan for Patients with IgA Nephropathy
March 16, 2021 | finance.yahoo.com

Chinook Therapeutics, Inc. Rings the Nasdaq Stock Market Closing Bell
March 5, 2021 | nasdaq.com

Will Chinook Therapeutics (KDNY) Report Negative Q4 Earnings? What You Should Know
March 1, 2021 | finance.yahoo.com

Chinook Therapeutics and Evotec Announce Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases
March 1, 2021 | finance.yahoo.com

Evotec, Chinook Collaborate To Discover & Develop Medicines For Chronic Kidney Diseases
March 1, 2021 | nasdaq.com

Chinook Therapeutics to Present at 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit
February 23, 2021 | finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.41 out of 5 stars

Medical Sector

647th out of 2,016 stocks

Pharmaceutical Preparations Industry

308th out of 771 stocks

3.5 Analyst's Opinion

Consensus Rating
Chinook Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $30.33, Chinook Therapeutics has a forecasted upside of 118.4% from its current price of $13.89.
Amount of Analyst Coverage
Chinook Therapeutics has only been the subject of 1 research reports in the past 90 days.

2.9 Community Rank

Outperform Votes
Chinook Therapeutics has received 11 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Chinook Therapeutics has received 8 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Chinook Therapeutics has received 57.89% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Chinook Therapeutics and other stocks. Vote “Outperform” if you believe KDNY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KDNY will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Chinook Therapeutics does not currently pay a dividend.
Dividend Growth
Chinook Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Chinook Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.90% of the stock of Chinook Therapeutics is held by insiders.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Chinook Therapeutics are expected to grow in the coming year, from ($1.97) to ($1.96) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Chinook Therapeutics is -3.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Chinook Therapeutics is -3.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Chinook Therapeutics has a P/B Ratio of 3.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$13.89

+0.29 (+2.13 %)

(As of 04/13/2021 01:20 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive KDNY News and Ratings via Email

Sign-up to receive the latest news and ratings for KDNY and its competitors with MarketBeat's FREE daily newsletter.

Chinook Therapeutics (NASDAQ:KDNY) Frequently Asked Questions

Is Chinook Therapeutics a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chinook Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Chinook Therapeutics stock.
View analyst ratings for Chinook Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Chinook Therapeutics?

Wall Street analysts have given Chinook Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Chinook Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Chinook Therapeutics' next earnings date?

Chinook Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 3rd 2021.
View our earnings forecast for Chinook Therapeutics.

How were Chinook Therapeutics' earnings last quarter?

Chinook Therapeutics, Inc. (NASDAQ:KDNY) released its earnings results on Tuesday, April, 6th. The company reported ($1.24) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by $0.82. Chinook Therapeutics had a negative net margin of 215.80% and a negative trailing twelve-month return on equity of 112.72%.
View Chinook Therapeutics' earnings history.

What price target have analysts set for KDNY?

8 analysts have issued 12-month target prices for Chinook Therapeutics' stock. Their forecasts range from $25.00 to $38.00. On average, they anticipate Chinook Therapeutics' share price to reach $30.33 in the next twelve months. This suggests a possible upside of 118.1% from the stock's current price.
View analysts' price targets for Chinook Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Chinook Therapeutics' key executives?

Chinook Therapeutics' management team includes the following people:

Mr. Eric L. Dobmeier, Pres, CEO & Director (Age 52)
Mr. Ali Haddarah, Group Chief Financial Officer
Ms. Noopur Batsha Liffick, VP of Investor Relations & Corp. Communications
Mr. Kirk D. Schumacher J.D., Sr. VP & Gen. Counsel
Ms. Jodi Jamieson, VP of HR
Mr. Tom Frohlich, Chief Bus. Officer
Mr. Alan Glicklich M.D., Chief Medical Officer
Mr. Andrew James King D.V.M., Ph.D., Head of Renal Discovery & Translational Medicine
Ms. Renata Oballa Ph.D., VP of Research Operations & Vancouver Site Head

Who are some of Chinook Therapeutics' key competitors?

Some companies that are related to Chinook Therapeutics include Amarin (AMRN), Xencor (XNCR), Prestige Consumer Healthcare (PBH), Arcus Biosciences (RCUS), Dicerna Pharmaceuticals (DRNA), Revance Therapeutics (RVNC), Axsome Therapeutics (AXSM), IGM Biosciences (IGMS), CytoDyn (CYDY), Kura Oncology (KURA), NGM Biopharmaceuticals (NGM), Madrigal Pharmaceuticals (MDGL), Morphic (MORF), Seres Therapeutics (MCRB) and FibroGen (FGEN).
View all of KDNY's competitors.

What other stocks do shareholders of Chinook Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chinook Therapeutics investors own include BioSyent (RX) and Continental Resources (CLR).

What is Chinook Therapeutics' stock symbol?

Chinook Therapeutics trades on the NASDAQ under the ticker symbol "KDNY."

How do I buy shares of Chinook Therapeutics?

Shares of KDNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chinook Therapeutics' stock price today?

One share of KDNY stock can currently be purchased for approximately $13.91.

How much money does Chinook Therapeutics make?

Chinook Therapeutics has a market capitalization of $589.46 million and generates $17.26 million in revenue each year. The company earns $-82,370,000.00 in net income (profit) each year or ($5.15) on an earnings per share basis.

How many employees does Chinook Therapeutics have?

Chinook Therapeutics employs 43 workers across the globe.

What is Chinook Therapeutics' official website?

The official website for Chinook Therapeutics is chinooktx.com.

Where are Chinook Therapeutics' headquarters?

Chinook Therapeutics is headquartered at 740 HEINZ AVENUE, BERKELEY CA, 94710.

How can I contact Chinook Therapeutics?

Chinook Therapeutics' mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The company can be reached via phone at 510-848-4400 or via email at [email protected]

This page was last updated on 4/13/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here